Neurocrine Biosciences Inc and Takeda Pharmaceutical Co Ltd Announce Collaboration to Develop and Commercialize Potential Therapies for Psychiatric Disorders Transcript
Good day, everyone, and welcome to today's Neurocrine Biosciences company update. (Operator Instructions) Please note, this call may be recorded. (Operator Instructions) It is my pleasure to turn the program over to Todd Tushla.
Thanks, Leo. Good morning, everyone, and thank you for joining our call today on short notice to discuss the collaboration we announced earlier this morning with Takeda.
During today's call, we will be making forward-looking statements. These statements are subject to certain risks and uncertainties and our actual results may differ materially. I encourage you to review the risk factors discussed in our latest SEC filings.
Joining me on the call today is Kevin Gorman, our Chief Executive Officer; Kyle Gano, our Chief Business Development and Strategy Officer; Eiry Roberts, our Chief Medical Officer; Matt Abernethy, our Chief Financial Officer; Eric Benevich, our Chief Commercial Officer; and Jaz Singh, our Vice President of Clinical Development. During this call,
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |